potent HIV-1 protease inhibitor
in vitro activity (IC50 = 0.0071 μM, EC50 = 0.86 μM)
from “pocket-to-lead” virtual screen and SBDD
J. Med. Chem.
Shionogi, Osaka, JP
Context. “Compound 14” (Shionogi) is an HIV-1 protease inhibitor being developed for HIV treatment. Despite the existence of two generations and a total of nine approved agents targeting the…